

Human ALK-7 Protein

Cat. No. ALK-HM107



Description

Source	Recombinant Human ALK-7 Protein is expressed from HEK293 with His tag at the C-terminus. It contains Glu21-Glu113.
Accession	Q8NER5-1
Molecular Weight	The protein has a predicted MW of 11.11 kDa. Due to glycosylation, the protein migrates to 20-40 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22 µm filtered solution in 20mM Tris, 150mM NaCl (pH 7.5). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Arterial stiffness is an important feature of diabetic macrovascular complications. Activin receptor-like kinase 7 (ALK7), a member of type I transforming growth factor- β (TGF- β) receptors, is correlated with pathogenic risks of type 2 diabetes mellitus and cardiovascular diseases and may be involved in cardiovascular remodeling.


Assay Data

Tris-Bis PAGE



Human ALK-7 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human ALK-7 is greater than 95% as determined by SEC-HPLC.